1. [18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis
- Author
-
Ying Xu, Ru Yao, Zhixin Hao, Fangyuan Chen, Bowen Liu, Qiang Sun, Bo Pan, Li Huo, and Yidong Zhou
- Subjects
Breast Cancer ,[18F]F-FES PET/CT ,Endocrine therapy ,Estrogen receptor ,Meta-analysis ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background This meta-analysis evaluates the diagnostic and staging accuracy of [18F]F-FES PET/CT, its ability to detect estrogen receptor (ER) positivity, and its effectiveness in predicting response to endocrine therapy in ER-positive (ER+) breast cancer. A systematic search of PubMed, Embase (OVID), and Web of Science databases was conducted for studies published between 2013 and June 2024. Studies involving ER + breast cancer patients who underwent [18F]F-FES PET/CT were included. We analyzed the diagnostic accuracy, ER detection capability, and predictive ability for endocrine therapy response. Results Out of 189 studies initially identified, 21 met the inclusion criteria. For diagnosis and staging compared to [18F]F-FDG PET (10 studies), [18F]F-FES PET/CT demonstrated a sensitivity of 0.75 (95% CI: 0.62–0.85) and a false positive rate (FPR) of 0.27 (95% CI: 0.09–0.50). For ER detection (7 studies), sensitivity was 0.86 (95% CI: 0.71–0.94) with an FPR of 0.45 (95% CI: 0.19–0.73). For predicting response to endocrine therapy (12 studies), [18F]F-FES PET/CT showed a sensitivity of 0.79 (95% CI: 0.62–0.89) and an FPR of 0.58 (95% CI: 0.42–0.72). Conclusions [18F]F-FES PET/CT is valuable for diagnosing and staging ER + breast cancer, assessing ER status, and predicting response to endocrine therapy. Its implementation can improve treatment planning and patient outcomes in breast cancer management.
- Published
- 2025
- Full Text
- View/download PDF